Jan. 6 at 8:30 PM
Attached is a history of biopharma M&A exits announced at JP Morgan, or a few weeks later, going back to 1/1/17. Since we primarily track commercial-stage biopharma M&A, of course it is possible our attached list is missing the acquisition of a clinical-stage bio.
We continue to believe
$SNDX is an obvious M&A candidate by Incyte. It's been 17 months since Niktimvo was approved & 14 months since Revuforj's 1st approval. If you follow us, you know those commercial-stage oncology focused bio M&A exits that deliver meaningful gains to shareholders are acquired within 2 years of 1st FDA approval...versus 3 years in non-oncology.
We believe other compelling M&A candidates, again candidates because at best we're guessing, for next week include;
$URGN
$TARS
$MIRM
$NUVB
We excluded GWPH & VIE acquired in early February 2021 (when the XBI was at a 5-year high).
As always, don't take us too seriously. This is not investment advice. Do your own due diligence.
